Download 11.8.11 seminar_Lehrer (PDF)

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Psychoneuroimmunology wikipedia , lookup

Transmission (medicine) wikipedia , lookup

Immunomics wikipedia , lookup

Neglected tropical diseases wikipedia , lookup

Molecular mimicry wikipedia , lookup

Infection control wikipedia , lookup

Hygiene hypothesis wikipedia , lookup

Herd immunity wikipedia , lookup

Childhood immunizations in the United States wikipedia , lookup

Infection wikipedia , lookup

Globalization and disease wikipedia , lookup

Orthohantavirus wikipedia , lookup

Henipavirus wikipedia , lookup

Ebola virus disease wikipedia , lookup

Hepatitis B wikipedia , lookup

DNA vaccination wikipedia , lookup

Vaccine wikipedia , lookup

Vaccination wikipedia , lookup

Immunocontraception wikipedia , lookup

Transcript
Department of Tropical Medicine Medical Microbiology & Pharmacology
Pacific Center for Emerging Infectious Diseases Research
Well
COBRE/Department of Tropical Medicine Seminar Series
Recombinant Viral Proteins Expressed in
Insect Cells and their Application for
Vaccine Development
Vaccine safety is becoming an increasingly important criterion for newly
developed vaccines for neglected, emerging or re-emerging infectious diseases
or for next-generation products replacing existing vaccines. Properly selected
and highly purified recombinant antigens can fill these needs, if antigen design
and dosing are adjusted to be sufficiently immunogenic to prevent viral infection
or at least prevent the onset of clinical disease. As an example, there are
currently no licensed vaccines to prevent the hemorrhagic fevers resulting from
Ebola or Marburg virus infection. Classical approaches such as inactivated
whole-virus vaccines carry significant safety risks and efforts at developing these
or attenuated virus vaccines have proven unsuccessful. We have produced
multiple recombinant subunit filovirus antigens in insect cells that have been
shown to elicit potent humoral and cell-mediated immune responses in mice,
guinea pigs and non-human primates when formulated with proper adjuvants.
Lead candidate vaccines have shown complete protection against live Ebola
virus challenge, when tested in rodent models. The modular aspect of this
recombinant subunit vaccine allowed us to demonstrate the contributions of
humoral and cellular immunity in protection elicited by recombinant Ebola virus
glycoprotein and VP24 subunits in mice.
Axel Lehrer, Ph.D.
Project Manager and Lead Scientist
Pan Thera Biopharma
Aiea, Hawaii
Tuesday, November 8, 2011 at 10:30 a.m.
John A. Burns School of Medicine, Kaka‘ako
Medical Education Building Auditorium, Room 315
For further information, call 692-1654
The Center and its activities are supported by grants P20RR018727 and
G12RR003061 from the National Center for Research Resources,
National Institutes of Health